Yulia Sergeevna Burykina

Dr. Yulia Sergeevna Burykina

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
LGLeila Gandaeva
Leila Gandaeva
EBElena N. Basargina
Elena N. Basargina
YDYulia I. Davydova
Yulia I. Davydova
YBYulia Sergeevna Burykina
Yulia Sergeevna Burykina
ИСИрина В. Сильнова
Ирина В. Сильнова
KSKirill Savostyanov
Kirill Savostyanov
Introduction. Acyl-CoA dehydrogenase 9 deficiency (mitochondrial complex I deficiency) is an autosomal recessive disease from the heterogeneous group of disorders of mitochondrial β-oxidation of fatty acids caused by mutations in the ACAD9 gene. The disease is characterized by a wide range of clinical manifestations, the most common of which are metabolic acidosis, hypertrophic cardiomyopathy, muscle hypotonicity, and impaired motor skills. The article presents the first Russian clinical observation of a rare variant of hypertrophic cardiomyopathy with early debut in a patient with mitochondrial complex I deficiency caused by homozygous mutation c.659C>T (p.A220V) in the ACAD9 gene and emphasizes the importance of early diagnosis of the disease and complex drug therapy to prevent the development of severe complications. Objective: to describe the clinical course and management of a patient with the pathogenic c.659C>T (p.A220V) variant of the ACAD9 gene. Detailed analysis of anamnesis data, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic research performed using high-throughput sequencing and direct Sanger sequencing technology. The article presents a literature review and detailed data on clinical observation of a child with homozygous c.659C>T (p.A220V) mutation in the ACAD9 gene diagnosed on the basis of the cardiology department of the National Medical Research Center for Children’s Health. Early disease markers and possibilities of complex drug therapy to prevent the development of severe complications are described. Conclusion. Disruption of mitochondrial beta-oxidation of fatty acids is a heterogeneous group of inherited diseases due to abnormal mitochondrial beta-oxidation and transport of carnitine and fatty acids in mitochondria. A feature of these diseases is the multisystem nature of the lesion and its progressive course. In some cases, the initial clinical manifestations may be various disorders of the cardiovascular system (cardiomyopathy, heart rhythm disturbances), which may cause death in neonatal period and early childhood. Early molecular genetic research provides accurate diagnosis and, accordingly, timely prescription of complex therapy.

Verified
Journal Article
Open access
PDF file
YBYulia Sergeevna Burykina
Yulia Sergeevna Burykina
Daria ChudakovaDaria Chudakova
Daria Chudakova
OZOlga Zharova
Olga Zharova
EBElena Basargina
Elena Basargina
ISIrina Silnova
Irina Silnova
KSKirill Savostyanov
Kirill Savostyanov
Here, we present a unique case of the combination of two rare hereditary diseases—a familial form of dilated cardiomyopathy (DCM) and arterial calcification (AC)—in a 10-month-old boy. DCM was caused by a novel pathogenic nucleotide variant (NV) c.542G>T in the MYH7 gene, and AC was caused by biallelic nucleotide variants c.3421C>T and c.4015C>T in the ABCC6 gene. NVs were identified by the next-generation sequencing (NGS) of a broad panel of 404 genes potentially involved in cardiovascular disorders and subsequently validated by Sanger sequencing in the proband and his parents. Cardiologic examinations confirmed the familial nature of cardiomyopathy and the pathogenicity of variant c.542G>T in MYH7 gene. This case highlights the clinical utility of NGS in identifying complex co-existing hereditary conditions and emphasizes the need for the comprehensive genetic testing of patients with atypical clinical presentations.

31 January 2026 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
YBYulia Sergeevna Burykina
Yulia Sergeevna Burykina
NSNataliya Sdvigova
Nataliya Sdvigova
ЕБЕлена Николаевна Басаргина
Елена Николаевна Басаргина
ОГОксана Валерьевна Глоба
Оксана Валерьевна Глоба
AKAleksey L. Kurenkov
Aleksey L. Kurenkov
KSKirill Savostyanov
Kirill Savostyanov
Introduction. The dilated cardiomyopathy (DCM) represents a group of myocardial disorders whose primary characteristics are dilation of the left ventricular cavity and impaired systolic function. Thanks to significant progress in the field of molecular genetics, over fifty genes responsible for the primary form of DCM have now been identified, with mutations in the MYH7 gene accounting for up to 50% of all genetically confirmed cases. Objective: to establish the clinical and genetic characteristics of the dilated cardiomyopathy caused by mutations in the MYH7 gene in children.Materials and Methods. This study analyzed data from 250 DCM children examined at the Cardiology department of the National Medical Research Center for Children’s Health of the Ministry of Health from 2015 to 2024. The investigation employed modern molecular genetic diagnostic methods and comprehensive clinical and instrumental examination, with assessment of clinical dynamics over a 5-year period.Results. Isolated MYH7-associated DCM was confirmed in 80 (40,8%) unrelated children with identified causative variants. The clinical characteristics of the disease include early onset (over 80% of cases manifesting within the first year of life), frequent combination with non-compaction of the myocardium (85%), and the development of left ventricular reverse remodeling following treatment.Variants in exons 19–23 were established to be associated with severe mitral regurgitation, requiring surgical intervention at an early age. In 3 cases, a rare combination of cardiomyopathy and myopathy was observed.Conclusion. The study confirms the significant role of pathogenic variants in the MYH7 gene in the development of cardiomyopathy in children. MYH7-associated forms of the disease with timely and appropriate drug therapy are characterized by a favorable prognosis, as evidenced by the high 5-year survival rate (97,4%) in patients. Molecular genetic testing is important in verifying the diagnosis, managing an early screening of relatives, and predicting the course of disease. The systematization of clinical and genetic characteristics creates the foundation for the devilment of personalized treatment approaches. A multidisciplinary approach to managing patients with cardiomyopathy and extracardiac manifestations is of particular importance.Compliance with ethical standards. The study was conducted in accordance with the ethical standards of the Declaration of Helsinki of 1975 and was approved by the Local Ethics Committee of the National Medical Research Center for Children’s Health of the Ministry of Health of Russia (Protocol No. 10, dated August 28, 2020). Informed consent was obtained from all participants or their legal representatives.Contribution:Burykina Yu.S. — concept and design of the study, collection and processing of material, text editing;Sdvigova N.A. — concept and design of the study, collection and processing of material, text editing;Basargina E.N. — text editing;Globa O.V. — text editing;Kurenkov A.L. — text editing;Zhanin I.S. — text editing;Pushkov A.A. — collection and processing of material, text writing;Savostyanov K.V. — concept and design of the study, text editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Acknowledgements. The authors express their gratitude to the patients’ families for supporting our research. The authors would like to express their gratitude to MD, Professor A.P. Fisenko, Director of the National Medical Research Center for Children’s Health of the Ministry of Health of the Russian Federation for his support and technical assistance in implementation of this work. The authors would like to thank the entire staff of the National Medical Research Center for Children’s Health of the Ministry of Health of the Russian Federation for the opportunity of interdisciplinary approach to patients care.Received: October 8, 2025Accepted: December 1, 2025Published: January 31, 2026

29 April 2026 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
YBYulia Sergeevna Burykina
Yulia Sergeevna Burykina
LGLeila Gandaeva
Leila Gandaeva
IDIu. I. Davydova
Iu. I. Davydova
OGO. V. Globa
O. V. Globa
ОСО. П. Савельев
О. П. Савельев
KSKirill Savostyanov
Kirill Savostyanov
Bloom-like syndrome is a rare autosomal recessive disorder caused by nucleotide variants in the TOP3A gene. It is characterized by clinical manifestations similar to Bloom syndrome, including a characteristic facial phenotype and physical development delay, but diff ers in the more frequent development of a dilated cardiomyopathy. These syndromes belong to the group of hereditary diseases associated by impaired DNA repair. Given the existence of isolated clinical cases with a predominant description of characteristic physical development delay, a detailed description of the course of dilated cardiomyopathy is signifi cant for understanding the disease and optimizing medical treatment. Here is a description of the clinical course and features of the child’s management with a homozygous mutation c.2264_2265delinsT in the TOP3A gene, examined at the cardiology department of the National Medical Research Center of Children’s Health of the Ministry Health of the Russian Federation. An analysis of anamnesis data, including family history, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic testing performed using Sanger direct sequencing technology, was conducted. A literature review of patients with mutations in the TOP3A gene was conducted. The presented clinical case demonstrates the importance of timely diagnosis of the disease, the high frequency of cardiac manifestations, particularly the steadily progressive and fatal course of dilated cardiomyopathy. In childhood, dilated cardiomyopathy can be a dominant and life-threatening manifestation of TOP3A -associated Bloom-like syndrome. Given the risk of a sudden and aggressive course of dilated cardiomyopathy, identifying mutations in the TOP3A gene in children with physical development delay and a characteristic «bird-like» facies has important prognostic value. Improving the prognosis requires early diagnosis, including prenatal diagnosis in high-risk families, the development of pathogenetic therapy, and a multidisciplinary approach to patient management.